Incidence of adverse cardiac event defined as decrease in LVEF by ≥ 10% or elevated HsTnT levels in DLBCL patients treated with either CHOP+/-R or CEpOP+/-R. While changes in LVEF were similar between treatment arms, a significantly higher number of patients in the CHOP+/-R group exhibited elevation of HsTnT levels after 4 cycles of planed therapy. *P = 0.001